Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anebulo Pharmaceuticals Inc
(NQ:
ANEB
)
1.980
+0.040 (+2.06%)
Streaming Delayed Price
Updated: 3:44 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Anebulo Pharmaceuticals Inc
< Previous
1
2
Next >
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
July 22, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
July 01, 2024
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board
From
Lifecore Biomedical, Inc.
Via
GlobeNewswire
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
May 15, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
February 13, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
November 14, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces New CEO
October 06, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
October 06, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
September 20, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
August 30, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
August 21, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
February 10, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
January 09, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
November 10, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
November 01, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing
September 26, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
September 26, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022
September 20, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress
September 09, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26
August 23, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
July 05, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
June 23, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
May 24, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
May 11, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
April 01, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
February 11, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
January 06, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
January 06, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
January 04, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
January 03, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
November 12, 2021
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.